Clinical trial
A phase II study to investigate the efficacy of RAD001 (Afinitor�, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma
To determine the efficacy of RAD001 in patients with progressive irresectable recurrent or metastatic differentiated thyroid carcinoma
| Category | Value |
|---|---|
| Study start date | 2010-01-28 |